

PRISM MEDICO AND PHARMACY LIMITED

CIN: L51109HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Date: 13.08.2022

To, Department of Corporate Services, BSE LIMITED P. J. Towers, Dalal Street, Mumbai, Maharashtra-400 001 ISIN : INE730E01016 Scrip Code: 512217	To, Listing Department, Metropolitan Stock Exchange of India Limited (MSEI) Vibgyor Towers, 4th Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. SYMBOL: PRISMEDI
---	--

Dear Sir / Madam,

Subject: Outcome of the Board Meeting – Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 13th August, 2022) which commenced at 03:00 P.M. and concluded at 04:30 P.M. have inter alia approved the following:

- The Board considered and approved the Unaudited Standalone Financial Results for the Quarter ended 30th June, 2022 alongwith Limited Review Report duly signed by the Auditors of the company.

Kindly take on record the same and oblige.

Thanking You,
Yours Truly,

FOR PRISM MEDICO AND PHARMACY LIMITED



DAVENDER SINGH
DIRECTOR
DIN: 09447213